ATXI

Dopo l'orario di chiusura: .74

Avenue Therapeutics Inc (ATXI)

Panoramica Notizia Cronologia dei prezzi Financials Perché ATXI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Avenue Therapeutics Inc

Healthcare (1140)

Biotechnology (637)

Prossima data di guadagno

Ultimi documenti SEC

ATXI's Discussions on Twitter

Confronta ATXI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ATXI Avenue Therapeutics Inc	0.74	0	0	-10.38M	-12.45M	-3.81
VRTX Vertex Pharmaceuticals Inc	408.61	105.69B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	481.07	61.52B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	569.17	60.69B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	837.28	50.05B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	318.02	35.25B	4.56B	-176.77M	225.30M	-1.7177

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc Stock (ATXI) Company Profile

Confronta ATXI con altri titoli

Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times

Avenue Therapeutics (NASDAQ:ATXI) vs. ADVANZ PHARMA (OTCMKTS:CXRXF) Financial Analysis - Defense World

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - The Manila Times

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewswire

United States Drug Resistant Epilepsy Market 2025 | Industry Developments, Future Growth, Share & Industry Insights - openPR.com

Affiliate of Pacific Avenue Capital Partners Completes the Acquisition of Pick Your Part from LKQ Corporation - Shreveport Times

Park Avenue Securities LLC Has $212,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - Defense World

United Therapeutics Corporation $UTHR Stake Lifted by Park Avenue Securities LLC - Defense World

2,085 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Park Avenue Securities LLC - Defense World

Park Avenue Securities LLC Has $622,000 Stock Position in Halozyme Therapeutics, Inc. $HALO - Defense World

Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment - Yahoo Finance

Postoperative Pain Management Market to Expand Significantly by 2032, States DelveInsight Report - openPR.com

SpringWorks Therapeutics Inc.’s volatility index tracking explainedEarnings Overview Summary & Stock Portfolio Risk Management - newser.com

How hedge fund analytics apply to Janux Therapeutics Inc. stockWeekly Profit Summary & AI Optimized Trade Strategies - newser.com

Is TScan Therapeutics Inc. meeting your algorithmic filter criteria2025 Valuation Update & Safe Capital Growth Tips - newser.com

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol - IT Business Net

7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews

Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat

Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest

Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech

Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise

Coya Therapeutics to Participate at Upcoming September 2025 Investor Conferences - biospace.com

Coya Therapeutics to Participate at Upcoming September Investor Conferences - Stock Titan

How to escape a deep drawdown in Bicara Therapeutics Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser

FBIO In FocusWill CUTX-101 Make History As The First FDA-Approved Menkes Disease Therapy? - RTTNews

Plus Therapeutics Inc. stock trend forecastPortfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser

Abeona Therapeutics to expand in Midtown - NEO-Trans.blog

Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average PT from Analysts - MarketBeat

Has Anika Therapeutics Inc. formed a bullish divergenceJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser

Will Galectin Therapeutics Inc. stock recover after recent dropJuly 2025 Breakouts & High Conviction Trade Alerts - Newser

Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks

North American Morning Briefing : Stock Futures -2- - MarketScreener

Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN

XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada

Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail

Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com

Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com

Postoperative Pain Management Market to Expand Significantly - openPR.com

Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser

Delisting of Securities from The Nasdaq Stock Market - The Manila Times

Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN

112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha

656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 BillionWSJ - The Wall Street Journal

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider

Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a ATXI